Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Leases: 2019-2025

Historic Operating Leases for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Sep 2025 value amounting to $49.1 million.

  • Crinetics Pharmaceuticals' Operating Leases rose 8.90% to $49.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.1 million, marking a year-over-year increase of 8.90%. This contributed to the annual value of $44.6 million for FY2024, which is 6.28% down from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Operating Leases stood at $49.1 million for Q3 2025, which was up 13.43% from $43.3 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Operating Leases' 5-year high stood at $49.1 million during Q3 2025, with a 5-year trough of $1.5 million in Q2 2023.
  • Moreover, its 3-year median value for Operating Leases was $45.1 million (2024), whereas its average is $38.0 million.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 43.24% in 2023, then skyrocketed by 3,050.62% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Operating Leases (Quarterly) stood at $3.1 million in 2021, then crashed by 34.16% to $2.0 million in 2022, then soared by 2,249.56% to $47.6 million in 2023, then declined by 6.28% to $44.6 million in 2024, then climbed by 8.90% to $49.1 million in 2025.
  • Its last three reported values are $49.1 million in Q3 2025, $43.3 million for Q2 2025, and $43.9 million during Q1 2025.